Literature DB >> 11268357

Neural control of ocular immune privilege.

J W Streilein1, S Okamoto, Y Sano, A W Taylor.   

Abstract

Ocular immune privilege arises from interactions between the immune apparatus and the eye itself, thereby providing immune protection for the eye that is devoid of sight-threatening inflammation. On the one hand, antigens injected intraocularly elicit deviant systemic immune responses that are devoid of immunogenic inflammation (Anterior Chamber-Associated Immune Deviation, ACAID). On the other hand, the ocular microenvironment (aqueous humor, secreted by cells that surround this chamber) suppresses intraocular expression of immunogenic inflammation. Several lines of evidence indicate that ocular immune privilege is under neural control. First, aqueous humor contains neuropeptides (alpha-MSH, VIP, CGRP) that inhibit and alter the functional properties of T lymphocytes and macrophages. Second, when corneal nerves are severed, the tissues surrounding the anterior chamber cease secreting immunosuppressive factors and ACAID fails--until the nerves regrow. Third, light deprivation abolishes the capacity of the anterior chamber to support ACAID induction, a process that is sensitive to neuropeptides and melatonin. The photoreceptor(s) responsible for ACAID are connected to the nervous system and may reside in the anterior segment and/or the retina. Thus, neural elements from the central nervous system and within the eye help to shape both the induction and the expression of ocular immunity, thereby promoting immune privilege.

Entities:  

Mesh:

Year:  2000        PMID: 11268357     DOI: 10.1111/j.1749-6632.2000.tb05396.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  19 in total

1.  The relation between C reactive protein and age related macular degeneration in the Cardiovascular Health Study.

Authors:  G McGwin; T A Hall; A Xie; C Owsley
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

Review 2.  [Systemic immunosuppressives after penetrating keratoplasty].

Authors:  A Reis; F Birnbaum; T Reinhard
Journal:  Ophthalmologe       Date:  2007-05       Impact factor: 1.059

Review 3.  Translational Immunoimaging and Neuroimaging Demonstrate Corneal Neuroimmune Crosstalk.

Authors:  Pedram Hamrah; Yashar Seyed-Razavi; Takefumi Yamaguchi
Journal:  Cornea       Date:  2016-11       Impact factor: 2.651

4.  CD55 Is Essential for CD103+ Dendritic Cell Tolerogenic Responses that Protect against Autoimmunity.

Authors:  Michael G Strainic; Jinbo Liu; Fengqi An; Erin Bailey; Andrew Esposito; Jörg Hamann; Peter S Heeger; M Edward Medof
Journal:  Am J Pathol       Date:  2019-05-17       Impact factor: 4.307

Review 5.  NLRs in immune privileged sites.

Authors:  Holly L Rosenzweig; Stephen R Planck; James T Rosenbaum
Journal:  Curr Opin Pharmacol       Date:  2011-07-29       Impact factor: 5.547

6.  Role of VIP and Sonic Hedgehog Signaling Pathways in Mediating Epithelial Wound Healing, Sensory Nerve Regeneration, and Their Defects in Diabetic Corneas.

Authors:  Yangyang Zhang; Nan Gao; Lin Wu; Patrick S Y Lee; Rao Me; Chenyang Dai; Lixin Xie; Fu-Shin X Yu
Journal:  Diabetes       Date:  2020-04-28       Impact factor: 9.461

Review 7.  Corneal lymphangiogenesis in herpetic stromal keratitis.

Authors:  Paul J Park; Michael Chang; Nitin Garg; Jimmy Zhu; Jin-Hong Chang; Deepak Shukla
Journal:  Surv Ophthalmol       Date:  2014-06-10       Impact factor: 6.048

Review 8.  Glaucoma.

Authors:  Gülgün Tezel; Martin B Wax
Journal:  Chem Immunol Allergy       Date:  2007

Review 9.  Bilateral Alterations in Corneal Nerves, Dendritic Cells, and Tear Cytokine Levels in Ocular Surface Disease.

Authors:  Takefumi Yamaguchi; Pedram Hamrah; Jun Shimazaki
Journal:  Cornea       Date:  2016-11       Impact factor: 2.651

10.  Injection of an alpha-melanocyte stimulating hormone expression plasmid is effective in suppressing experimental autoimmune uveitis.

Authors:  D J Lee; D J Biros; A W Taylor
Journal:  Int Immunopharmacol       Date:  2009-05-06       Impact factor: 4.932

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.